Additionally, the combined use of natural compounds with drugs proven to have renoprotective effects (e.g., SGLT2 inhibitors, GLP-1 receptor agonists, or RAAS blockers) may exert synergistic effects in improving lipid metabolism and delaying DKD progression. Here, SLC5A2 is linked to diabetic kidney disease.